CD70 combination therapy
Assigneeargenx BV
InventorsLuc Van Rompaey, Mahan Moshir, Tim Delahaye, Piotr Zabrocki
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1R3/1L1RAP and CD47.
Claims18
A combination comprising a first antibody molecule that binds to CD70 and a second antibody molecule that binds to IL1RAP, wherein the first antibody molecule that binds to CD70 comprises a first variable heavy chain domain (VH) comprising the heavy chain complementarity determining region (HCDR) 1 (HCDR1), HCDR2 and HCDR3 amino acid sequences set forth in SEQ ID NO:
- 4, and a first variable light chain domain (VL) comprising the light chain complementarity determining region (LCDR) 1 (LCDR1), LCDR2 and LCDR3 amino acid sequences set forth in SEQ ID NO:
- 8, and wherein the second antibody molecule that binds to IL1RAP comprises:
- (i) a second VH comprising the HCDR1, HCDR2 and HCDR3 amino acid sequences set forth in SEQ ID NO:
- 121, and a second VL comprising the LCDR1, LCDR2 and LCDR3 amino acid sequences set forth in SEQ ID NO:
- 122;
- or
- (ii) a second VH comprising the HCDR1, HCDR2 and HCDR3 amino acid sequences set forth in SEQ ID NO:
- 123, and a second VL comprising the LCDR1, LCDR2 and LCDR3 amino acid sequences set forth in SEQ ID NO:
- 124.
A combination comprising a first antibody molecule that binds to CD70 and a second antibody molecule that binds to IL1RAP, wherein:
- (a) the first antibody molecule that binds to CD70 comprises a first VH comprising HCDR1, HCDR2 and HCDR3 regions, and a first VL comprising LCDR1, LCDR2 and LCDR3 regions, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of the first VH and first VL comprise the amino acid sequences set forth in SEQ ID NOs:
- 1, 2, 3, 5, 6, and 7, respectively;
- and
- (b) the second antibody molecule that binds to IL1RAP comprises:
- (i) a second VH comprising HCDR1, HCDR2 and HCDR3 regions, and a second VL comprising LCDR1, LCDR2 and LCDR3 regions, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of the second VH and second VL comprise the amino acid sequences set forth in SEQ ID NOs:
- 125, 126, 127, 131, 132, and 133;
- or 128, 129, 130, 134, 135, and 136, respectively.
Dependencies are inferred from the claim text.